Bristol Confident To Move Deucravacitinib Into Phase III Lupus Trial

 
• By Jessica Merrill
Lupus Ribbon
Bristol Myers is moving its TYK2 inhibitor into Phase III in lupus • Source: Shutterstock

More from Clinical Trials

More from R&D